INTRODUCTION
Maternal milk diets are ideal for all infants, particularly for vulnerable populations including very low birth weight (VLBW) infants. Observational studies over the past 30 years in preterm infants have reported myriad benefits from maternal milk diets compared with contemporary formula options, including better feeding tolerance, lower rates of sepsis [1, 2] , necrotizing enterocolitis (NEC) [1] [2] [3] [4] [5] , and bronchopulmonary dysplasia [2, 6] , shorter length of hospital stay [2] , fewer re-hospitalizations [6] , and superior developmental outcomes at 2-8 years of age [6] [7] [8] , with the demonstration of a significant dose-response relationship [6, 8] .
With an increased understanding of the importance of human milk for VLBW infants, the use of pooled, pasteurized donor human milk has rapidly gained acceptance. Most donor milk used in the United States is obtained from the member banks of the Human Milk Banking Association of North America -a nonprofit organization. In 2003, six banks were dispensing milk; in late 2014, there were 18 banks, with 10 more banks in various stages of development [9] . Between 2007 and 2011, the total volume of donor milk dispensed by Human Milk Banking Association of North America (HMBANA) banks doubled from 1.1 to 2.18 million ounces [9] .
Recent recommendations have been published from the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) [10] , the American Academy of Pediatrics (AAP) [11] , and the WHO [12] , endorsing the use of human donor milk in preterm infants when maternal milk is unavailable. Despite these recommendations and widespread use, large-scale studies of its use in VLBW infants during the era of routine human milk fortification are lacking. In 2011, the US Surgeon General called for further research to identify areas where the evidence regarding donor milk is inconclusive and to develop evidence-based clinical guidelines for its use [13] .
The use of donor milk in neonatal ICUs (NICUs) is well established, and data from the United States suggest an increasing acceptance of this product. Additionally, single-center reports of short-term nutritional and health outcomes of VLBW infants fed donor milk have been published that will inform future studies. The exclusive human milk diet, utilizing human milk fortifier derived from human donor milk rather than from bovine sources, also represents an emerging dietary option for VLBW infants which has been studied in limited populations.
MATERNAL AND DONOR MILK USE IN US NEONATAL ICUS
The use of both maternal and donor human milk in US NICUs is common, and rates have increased in recent years. An analysis of the Centers for Disease Control and Prevention's National Maternity Practices in Infant Nutrition and Care (MPINC) survey for the years 2007-2011 was conducted to determine patterns of human milk (maternal and donor) use in US NICUs. Responses were available for more than 80% of all facilities providing delivery services in the United States during the years surveyed. Among level 2 and level 3-4 NICUs combined, the rates of low human milk usage (0-9% of infants fed human milk) declined from 8% in 2007 to 7.3% in 2011, and rates of high human milk usage (>90% of infants fed human milk) increased from 21.2% in 2007 to 30.8% in 2011. Use of human donor milk increased faster than use of all human milk combined, with 11.5% of units reporting use in 2007, and 22% reporting use in 2011. This increase in donor milk use was most pronounced in the level 3 and 4 centers, where use increased from 25.1% in 2007 to 45.2% in 2011 [14] .
Building on this analysis, two groups have recently published reports of the prevalence of donor milk use, and the criteria for use in US NICUs. Parker et al. [15] used purposive random sampling to conduct a mail survey of US level 3 NICU medical directors to assess patterns of donor milk use. Among the directors who were surveyed, 60.3% (182/302) responded, distributed equally across all US regions. Also, 42% of the directors reported the use of donor milk in their NICUs, with higher rates of use in the West (62%) and Midwest (47%), and lower use in the Northeast (23%) and South (36%). Among users of donor milk (76/182), 85% had been using the intervention for less than 5 years. Factors associated with donor milk use in multivariable analysis included at least 800 annual NICU admissions in the Midwest or West location. Availability of surgical care for NEC or designation as a safety net hospital was not associated with donor milk use in this analysis. The criteria used to initiate use were varied, but commonly included insufficient maternal milk supply, and infants below a specified birth weight (83%) and gestational age (75%). At least 50% of respondents agreed that donor milk should be used in infants born weighing less than 1500 g, and discontinued at 33-34 weeks' postmenstrual age, and that it should be used after surgery for NEC. The majority of donor milk-using units had a specified guideline for use (73%), required signed parental consent for use (84%), and had high parental acceptance of donor milk (67% of units reported <5% parental refusal) [15] .
Hagadorn et al. [16 & ] used an online survey design of medical directors of level 3 and 4 NICUs in the United States to describe policy-driven use of donor milk. Among them, 33% (153/459) completed the survey, 59% of whom reported use of donor milk in their unit. Similar to the earlier survey of medical directors undertaken by Parker et al. [15] , use of donor milk was associated with more NICU beds, higher annual admissions, and higher VLBW admissions. Additionally, as noted in MPINC, higher-level NICUs were more likely to provide donor milk (74% of level 4 NICUs vs. 53% of level 3 NICUs). Directors were also queried regarding reasons for donor milk use, with many citing desire to reduce the incidence of NEC (58%) as the most important reason. Directors of centers that did not provide donor milk reported expense as the most common reason for nonuse. Among them, 79% reported use of a formal policy to guide donor milk use, and policies were varied, but typically included
KEY POINTS
Donor milk is commonly used to prevent NEC, but its ability to do so when fortified with bovine-derived human milk fortifier is not well studied.
The exclusive human milk diet is associated with a lower incidence of NEC than diets containing formula, but it has not been compared to a diet containing human milk and bovine fortifier in the absence of preterm formula.
Growth can be compromised with the use of donor milk, but this can be overcome with careful attention to adequate protein and calorie fortification.
Further research is needed before donor milk and the exclusive human milk diet become the gold standard for VLBW nutritional management.
Donor human milk for very low birth weights Colaizy birth weight or gestational age criteria for both initiation and discontinuation of donor milk. Also, 91% of directors reported that donor milk was used outside of the written criteria at the physician's discretion [16 & ]. From these three studies, it is clear that donor human milk use in US NICUs is prevalent and growing, particularly over the past 5-10 years. NICUs caring for the smallest and sickest infants in the greatest numbers use donor milk more frequently, and often do so in an effort to reduce the incidence of NEC.
EVIDENCE REGARDING NECROTIZING ENTEROCOLITIS AND FORTIFIED DONOR MILK
Although the desire to prevent NEC is often cited as a reason to use donor milk by neonatologists, evidence for this effect is limited. The most often cited references for reduced NEC with donor milk compared to formula diets are meta-analyses of trials that were conducted prior to the routine use of multicomponent bovine milk-derived human milk fortifiers, which are now standard of care for VLBW infants [17, 18] . These trials compared unfortified donor milk to contemporary formulas. The only randomized trial of bovine-fortified donor milk compared to preterm formula was published by Schanler et al. [1] in 2005. Infants were randomized to receive preterm formula or fortified donor milk if maternal milk was insufficient. Infants receiving formula had a higher incidence of NEC (11%) than those receiving either entirely fortified maternal milk (6%), or fortified donor milk (6%), but this difference was not statistically different (P ¼ 0.27, formula vs. donor milk). Therefore, we have no clear evidence that the use of donor milk with bovinederived fortifier will result in decreased NEC. Rather, evidence is commonly extrapolated from data that bovine-fortified maternal milk is associated with lower rates of NEC than preterm formula [1, 2, 19] , but the effects of pooling and pasteurization on donor milk, including decreased levels of secretory IgA [20] [21] [22] , lactoferrin, and lysozyme [22] , make these extrapolations problematic.
EVIDENCE REGARDING NECROTIZING ENTEROCOLITIS AND THE EXCLUSIVE HUMAN MILK DIET
A recent published secondary analysis of the two previously published trials of the exclusive human milk (EHM) diet provide preliminary evidence that the use of human milk-derived human milk fortifier (HHMF) in a human milk diet (maternal or donor) may offer protection against NEC when compared to preterm formula. The individual trials will be first reviewed as background. The first report of the EHM diet in VLBW infants published by Sullivan et al. [23] in 2010 was an unblinded trial that randomized infants to receive either bovine fortifier for all maternal milk feedings and preterm formula if a supplement to maternal milk was required, or HHMF for all maternal milk feedings and HHMFfortified donor milk if a supplement to maternal milk was required. The bovine group experienced a higher incidence of NEC (11/69, 16% vs. 8/138, 6% in the human group; P ¼ 0.02). Additionally, surgical NEC was more common in the bovine group (7/69, 10% vs. 2/138, 1.4% in the human group; P ¼ 0.007) [23] . The combined outcome of NEC/late onset sepsis occurred at similar rates between bovine (30%) and human (30%) groups. The same group of investigators then conducted a blinded randomized trial of EHM diet vs. preterm formula in infants whose mothers never provided milk [24] . Fifty-three infants were included, 24 received formula, and 29 EHM diet. Five infants in the formula group (21%) developed NEC, compared to 1 (3%) in the bovine group (P ¼ 0.08), and surgical NEC occurred in only the bovine group (4/5 cases; P ¼ 0.04) [24] . Infants in the formula group in this trial experienced NEC at much higher rates than previously noted for exclusively formula-fed infants (21% vs. an 11% incidence for infants exclusively fed formula in the NICHD 'glutamine' trial [19] ), which should be noted when interpreting these results.
The investigators then performed a post-hoc analysis of the datasets combined [25 & ]. They found that NEC occurred more frequently in the groups receiving formula or bovine HMF, or a combination of both (16/93, 17%) than those receiving EHM (9/ 167, 5%; P ¼ 0.002). Surgical NEC (11/93, 12%) and mortality (7/93, 8%) were also more common in the bovine groups than those receiving an EHM diet (surgical NEC 2/167, 1%, P ¼ 0.0003; mortality 3/167, 2%, P ¼ 0.04) [25 & ]. Due to the small sample size of each trial, and the relatively high rates of NEC noted, these results should be interpreted with caution. However, taken together or separately, they suggest that avoidance of formula results in lower incidence of NEC. There has not been a pure comparison of the use of HHMF and bovine HMF in diets that otherwise contain only maternal milk or donor milk; thus it is unknown if the EHM diet offers any benefit over a human milk diet fortified with bovine HMF with regards to NEC prevention.
EVIDENCE REGARDING GROWTH IN VERY LOW BIRTH WEIGHT INFANTS FED DONOR MILK
Since growth is closely linked to long-term neurodevelopmental outcomes [26] , any diet in widespread use in VLBWs needs to result in appropriate growth. Evidence for this is limited. However, there are two published trials of growth in VLBWs fed bovinefortified donor milk [27] . In the initial randomized trial of donor milk as a supplement to maternal milk published by Schanler et al. [1] , growth was reported as a secondary outcome. A weight gain deficit of 3 g/kg was noted for infants fed maternal or donor milk compared to those fed formula, but no difference was noted between the donor and maternal groups, and length and head growth were similar across all three groups. Colaizy et al. [27] specifically studied growth in a cohort of VLBW infants fed varying proportions of maternal and donor milk. Infants receiving more than 75% of the in-hospital diet as donor milk experienced a weight z-score change of À0.84 vs. À0.56 for infants receiving more than 75% maternal milk (P ¼ 0.28). Infants in this trial also received levels of protein fortification in excess of those produced with manufacturer-directed bovine HMF use, through additional bovine HMF use or as single component protein powders [27] .
Hair et al. [28] studied a similar cohort of VLBW infants fed the exclusive human milk diet, and reported that with early use and rapid advancement of human HMF, weight gain of 24.8 g/kg/day was achieved, which exceeds most recommendations. Although 43% of their infants were small for gestational age at discharge or 40 weeks postmenstrual age [28] , the growth rates achieved with their protocol were better than those achieved in either of the initial EHM studies [23, 24] .
Therefore, it has been demonstrated that appropriate growth can be achieved with the use of donor milk diets, when both bovine and human HMF products are used, but that fortification beyond the traditional first step (24 kcal/oz) may be required.
ONGOING DONOR MILK RESEARCH
As called for by the US Surgeon General [13] , there are several ongoing randomized trials of donor milk vs. preterm formula in VLBW infants in North America. Unger et al. [29 & ] recently published the protocol for the randomized, blinded Donor milk for Improved Neurodevelopmental Outcomes (DoMINO) trial, which is currently completing follow-up. VLBW infants were randomized at birth to receive donor milk or preterm formula as a supplement if maternal milk was insufficient, or as the sole diet if the mother chose not to provide milk for 90 days or the duration of hospitalization. The primary outcome of the trial is the Cognitive Scale score of the Bayley Scales of Infant Development III (BSID III) at age 18-22 months, and the investigators hypothesize that infants randomized to donor milk will score 5 points higher than those randomized to formula. This trial also collected extensive in-hospital growth and outcome data [29 & ]. A similar trial is underway in Iowa, where Colaizy et al. also randomized VLBW infants at birth to donor milk or formula if maternal milk was insufficient or absent (clinicaltrials.gov NCT01232725), to assess the effect of donor milk on neurodevelopmental outcomes at 18-22 months. Finally, the NICHD Neonatal Research Network is also conducting a blinded, randomized trial of donor milk vs. preterm formula in VLBW infants whose mothers do not provide milk, or provide only small amounts in the first days after birth (clinicaltrials.gov NCT01534481), to assess the impact of donor milk on neurodevelopmental outcomes at age 22-26 months.
These three trials will be the first to investigate the neurodevelopmental outcomes of VLBW infants fed donor milk compared to those fed formula using blinded randomized trial designs in the era of routine milk fortification. A total of over 1100 infants will be included in the three trials combined, allowing secondary investigation of the growth and neonatal morbidity outcomes associated with donor milk diets.
CONCLUSION
What do we know about donor milk? Its use is common and is increasing rapidly. Although commonly used to prevent NEC, its ability to do so is not well studied in the era of routine milk fortification. The exclusive human milk diet is associated with a lower incidence of NEC compared to diets containing any preterm formula, but it has not been directly compared to diets containing human milk and bovine fortifier. Donor milk diets fortified with bovine or human milk-derived fortifier can result in appropriate growth for VLBW infants, if care is taken to provide adequate protein and calorie intake.
What questions remain? Further research is needed in a variety of areas to fully understand the role of donor milk in the nutritional care of VLBW infants. Current ongoing studies will assess the 18-24-month neurodevelopmental outcomes of former VLBW infants fed donor milk compared to those fed preterm formula. Additionally, we need to investigate the effects of donor milk fortified with bovine HMF on incidence of NEC compared to maternal milk. Further studies of the exclusive human milk diet are required to determine if this diet offers any added benefit for protection against NEC over a human milk diet fortified with bovine HMF but lacking formula.
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